AR-21

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAR-21
Drug Alias Name白喉，破伤风，无细胞百日咳，灭活小儿麻痹症，乙型肝炎（重组）和乙型流感嗜血杆菌b型结合疫苗，佐剂HexavacAR-21
ClassificationVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Toxoid vaccineVaccines > Biological material > Bacterial vaccine +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHepatitis BPoliomyelitisTetanus +[6] 
Global Approved IndicationsHepatitis BPoliomyelitisTetanus +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2000/10/23
Country/TerritoryEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesSanofi Pasteur Msd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi Pasteur Msd SncMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsHepatitis BPoliomyelitisTetanus +[6] 

Other Information

ATC CodeJ07CA
Related LinksN/A